ROCKET PHARMACEUTICALS, INC. RCKT

Rank #1936 · Nasdaq · $0.3B market cap

Audited by EISNERAMPER LLP, no going-concern flag in the latest filing.

Score

38.4

P/E

-1.0

P/B

0.54

ROE

-52.5%

Op. Margin

–%

Debt Ratio

13%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆

Average

P/E -1.0x, P/B 0.54x. Ranks in the top 52% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -52.5%. Ranks in the top 89% of the universe.

Safety ★★★★☆

Excellent

Debt ratio 13%. Ranks in the top 10% of the universe. Under 100% is generally considered a safe level.

Growth –

No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2015	–	$-0.0B	$-0.0B	$-0.0B	–	-26
2016	–	$-0.0B	$-0.1B	$-0.1B	–	-9
2017	–	$-0.0B	$-0.0B	$0.1B	–	52
2018	$0.0B	$-0.0B	$-0.0B	$0.0B	–	30
2019	$0.0B	$-0.1B	$-0.1B	$0.0B	–	369
2020	$0.0B	$-0.1B	$-0.1B	$0.0B	–	418
2021	$0.0B	$-0.1B	$-0.1B	$0.2B	–	45
2022	$0.0B	$-0.1B	$-0.1B	$0.3B	–	14
2023	$0.0B	$-0.2B	$-0.2B	$0.5B	–	12
2024	$0.0B	$-0.2B	$-0.2B	$0.5B	–	16
2025	$0.0B	$-0.3B	$-0.3B	$0.5B	–	13